pertussis vaccine


Summary: A suspension of killed Bordetella pertussis organisms, used for immunization against pertussis (WHOOPING COUGH). It is generally used in a mixture with diphtheria and tetanus toxoids (DTP). There is an acellular pertussis vaccine prepared from the purified antigenic components of Bordetella pertussis, which causes fewer adverse reactions than whole-cell vaccine and, like the whole-cell vaccine, is generally used in a mixture with diphtheria and tetanus toxoids. (From Dorland, 28th ed)

Top Publications

  1. Østergaard E, Sørensen C, Nielsen L, Stawski G. Elimination of interfering activity in serum samples in the Chinese hamster ovary pertussis serology assay. Clin Vaccine Immunol. 2008;15:1244-7 pubmed publisher
    ..Adding serum to the sample dilution buffer or precoating the microplates with serum did not influence the antibody titers in the serum samples. The method described may be used for routine applications. ..
  2. de Greeff S, Mooi F, Schellekens J, de Melker H. Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands. Pediatr Infect Dis J. 2008;27:218-23 pubmed publisher
    ..With prevention of severe pertussis among infants as focus, this effect should not be ignored in the discussion on future vaccination strategies for pertussis. ..
  3. Littmann M, Hülsse C, Riffelmann M, Wirsing von Konig C. Long-term immunogenicity of a single dose of acellular pertussis vaccine in paediatric health-care workers. Vaccine. 2008;26:2344-9 pubmed publisher
    Monitor the long-term immunogenicity of a single dose of acellular pertussis vaccine in health-care workers...
  4. White O, Rowe J, Richmond P, Marshall H, McIntyre P, Wood N, et al. Th2-polarisation of cellular immune memory to neonatal pertussis vaccination. Vaccine. 2010;28:2648-52 pubmed publisher
    ..We evaluated this issue as part of a small pilot study comparing infants receiving a monovalent acellular pertussis vaccine (aP) at birth or birth and at 1 month, followed by DTaP at 2, 4 and 6 months with infants receiving DTaP ..
  5. Banus S, Stenger R, Gremmer E, Dormans J, Mooi F, Kimman T, et al. The role of Toll-like receptor-4 in pertussis vaccine-induced immunity. BMC Immunol. 2008;9:21 pubmed publisher
    ..wP vaccination does not induce Ptx-IgG. A role for LPS in the efficacy of wP underlines the usefulness of LPS analogs to improve bacterial subunit vaccines such as aP. ..
  6. Komatsu E, Yamaguchi F, Abe A, Weiss A, Watanabe M. Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challenge model. Clin Vaccine Immunol. 2010;17:807-12 pubmed publisher
    ..Tohama expressing the alleles ptxA1 or ptxA2 and prn1 or prn2 and compared the efficacies of an acellular pertussis vaccine against the mutants in a mouse model. While the vaccine was effective against all of the B...
  7. Lee G, Riffelmann M, Wirsing von Konig C. Cost-effectiveness of adult pertussis vaccination in Germany. Vaccine. 2008;26:3673-9 pubmed publisher
    ..An adult formulation of an acellular pertussis vaccine is licensed and available for use in Germany...
  8. Broutin H, Viboud C, Grenfell B, Miller M, Rohani P. Impact of vaccination and birth rate on the epidemiology of pertussis: a comparative study in 64 countries. Proc Biol Sci. 2010;277:3239-45 pubmed publisher
    ..A better understanding of the role of repeat infections in pertussis transmission is critical to refine existing control strategies. ..
  9. Banus S, Bottema R, Siezen C, Vandebriel R, Reimerink J, Mommers M, et al. Toll-like receptor 4 polymorphism associated with the response to whole-cell pertussis vaccination in children from the KOALA study. Clin Vaccine Immunol. 2007;14:1377-80 pubmed
    ..A lower titer was associated with the minor allele of rs2770150, supporting a role for Toll-like receptor 4 in the antibody response to wP vaccination. ..

More Information


  1. Feunou P, Ismaili J, Debrie A, Huot L, Hot D, Raze D, et al. Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1. Vaccine. 2008;26:5722-7 pubmed publisher
    ..pertussis is able to induce protection, we have developed the live attenuated B. pertussis vaccine strain BPZE1 that protects mice upon a single intranasal administration...
  2. Knuf M, Schmitt H, Jacquet J, Collard A, Kieninger D, Meyer C, et al. Booster vaccination after neonatal priming with acellular pertussis vaccine. J Pediatr. 2010;156:675-8 pubmed publisher
    ..Thus, neonatal aP priming did not lead to immune tolerance to pertussis antigens. However, it elicited bystander interference on HBV, Hib, and diphtheria responses. ..
  3. Locht C, Mielcarek N. New pertussis vaccination approaches: en route to protect newborns?. FEMS Immunol Med Microbiol. 2012;66:121-33 pubmed publisher
    ..Recently, a live attenuated nasal Bordetella pertussis vaccine has been developed and undergone first-in-man clinical trials...
  4. Bouchez V, Caro V, Levillain E, Guigon G, Guiso N. Genomic content of Bordetella pertussis clinical isolates circulating in areas of intensive children vaccination. PLoS ONE. 2008;3:e2437 pubmed publisher
  5. Hees L, Afroukh N, Floret D. [Vaccination coverage among health care workers in the pediatric emergency and intensive care department of Edouard Herriot hospital in 2007, against influenza, pertussis, varicella, and measles]. Arch Pediatr. 2009;16:14-22 pubmed publisher
    ..Occupational physicians have a very important role to play in meeting this goal. ..
  6. Guiso N. Bordetella pertussis and pertussis vaccines. Clin Infect Dis. 2009;49:1565-9 pubmed publisher
    ..Universal adult booster immunization is now possible using pertussis acellular vaccines, which target-and are thus likely to control-the virulence of this bacterium. ..
  7. Quinn H, McIntyre P. The impact of adolescent pertussis immunization, 2004-2009: lessons from Australia. Bull World Health Organ. 2011;89:666-74 pubmed publisher
  8. McIntyre P, Wood N. Pertussis in early infancy: disease burden and preventive strategies. Curr Opin Infect Dis. 2009;22:215-23 pubmed publisher
    ..If shown to be safe and effective, immunization at birth has significant practical advantages. Different strategies (alone or combined) may be needed in different settings. ..
  9. de Vries R, Kretzschmar M, Schellekens J, Versteegh F, Westra T, Roord J, et al. Cost-effectiveness of adolescent pertussis vaccination for the Netherlands: using an individual-based dynamic model. PLoS ONE. 2010;5:e13392 pubmed publisher
    ..This study indicates that adolescent pertussis vaccination is likely to be a cost-effective intervention for The Netherlands. The model is suited to investigate further pertussis booster vaccination strategies. ..
  10. Dakic G, Kallonen T, Elomaa A, Pljesa T, Vignjevic Krastavcevic M, He Q. Bordetella pertussis vaccine strains and circulating isolates in Serbia. Vaccine. 2010;28:1188-92 pubmed publisher
    In Serbia, whole cell pertussis vaccine was introduced in 1957. Current composition of the vaccine has been used since 1985 and contains four autochthonous strains of Bordetella pertussis isolated from 1957 to 1984...
  11. Hallander H, Ljungman M, Storsaeter J, Gustafsson L. Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children. APMIS. 2009;117:797-807 pubmed publisher
    ..In a group of children given a two- or a five-component acellular pertussis vaccine the proportion of sera above the tentative cut-off values for anti-PT of 20, 50 or 100 EU/ml 12 months after ..
  12. Kavanagh H, Noone C, Cahill E, English K, Locht C, Mahon B. Attenuated Bordetella pertussis vaccine strain BPZE1 modulates allergen-induced immunity and prevents allergic pulmonary pathology in a murine model. Clin Exp Allergy. 2010;40:933-41 pubmed publisher
    ..pertussis mucosal vaccine, BPZE1, has been developed that evokes full protection against virulent challenge in mice but the effect of this attenuated strain on the development of allergic responses is unknown...
  13. Yano A, Komatsu T, Ishibashi M, Udaka K. Potent CTL induction by a whole cell pertussis vaccine in anti-tumor peptide immunotherapy. Microbiol Immunol. 2007;51:685-99 pubmed
    ..In order to induce more potent cytolytic CD8 T cell responses, we investigated the use of Bordetella pertussis vaccine as an adjuvant for peptide immunization...
  14. Oliveira M, Miyaji E, Ferreira D, Moreno A, Ferreira P, Lima F, et al. Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice. PLoS ONE. 2010;5:e10863 pubmed publisher
    ..Here, we have tested the adjuvant properties of the whole cell Bordetella pertussis vaccine (wP) that is currently part of the DTP (diphtheria-tetanus-pertussis) vaccine administrated to children in ..
  15. Bart M, van Gent M, van der Heide H, Boekhorst J, Hermans P, Parkhill J, et al. Comparative genomics of prevaccination and modern Bordetella pertussis strains. BMC Genomics. 2010;11:627 pubmed publisher
    ..Our work suggests that B. pertussis adapted by successive accumulation of SNPs and by gene (in)activation. In particular changes in gene regulation may have played a role in adaptation. ..
  16. Kallonen T, He Q. Bordetella pertussis strain variation and evolution postvaccination. Expert Rev Vaccines. 2009;8:863-75 pubmed publisher
    ..In this review, we present data on strain variation and evolution of B. pertussis in different vaccinated populations and summarize the common methods for typing of B. pertussis and their relative discriminatory power. ..
  17. van Gent M, de Greeff S, van der Heide H, Mooi F. An investigation into the cause of the 1983 whooping cough epidemic in the Netherlands. Vaccine. 2009;27:1898-903 pubmed publisher
    ..Further, we show that MLVA and fimbrial serotyping of strains can be used as early warning for pertussis epidemics...
  18. Advani A, Gustafsson L, Ahrén C, Mooi F, Hallander H. Appearance of Fim3 and ptxP3-Bordetella pertussis strains, in two regions of Sweden with different vaccination programs. Vaccine. 2011;29:3438-42 pubmed publisher
    ..Our results highlight the importance of strain typing to gain insight into the mechanisms of immunity-associated selection of microbial subtypes and the causes of changes in incidences of infectious diseases...
  19. Hellenbrand W, Beier D, Jensen E, Littmann M, Meyer C, Oppermann H, et al. The epidemiology of pertussis in Germany: past and present. BMC Infect Dis. 2009;9:22 pubmed publisher
    ..Nationwide pertussis reporting is required for better evaluation of transmission patterns and vaccination policy in both parts of Germany. ..
  20. Han H, Kuwae A, Abe A, Arakawa Y, Kamachi K. Differential expression of type III effector BteA protein due to IS481 insertion in Bordetella pertussis. PLoS ONE. 2011;6:e17797 pubmed publisher
    ..This type-dependent expression is due to an insertion of IS481 in B. pertussis clinical strains, suggesting that augmented expression of BteA protein might play a key role in the type shift of B. pertussis. ..
  21. Zhu Y, Li Q, Wang L, Zhong Y, Ding G, Li G, et al. Gene expression profiling-based in silico approach to identify potential vaccine candidates and drug targets against B. pertussis and B. parapertussis. OMICS. 2008;12:161-9 pubmed publisher
    ..Further researches focusing on the 191 vaccine candidates could accelerate the development of more effective vaccines and drug therapy against B.p and B.pp infection...
  22. Roberts R, Moreno G, Bottero D, Gaillard M, Fingermann M, Graieb A, et al. Outer membrane vesicles as acellular vaccine against pertussis. Vaccine. 2008;26:4639-46 pubmed publisher
    ..In view to their capacity to induce airways innate and protective immunity in the mouse model, OMVs obtained from B pertussis are candidates to be used to protect against pertussis. ..
  23. Campbell H, Amirthalingam G, Andrews N, Fry N, George R, Harrison T, et al. Accelerating control of pertussis in England and Wales. Emerg Infect Dis. 2012;18:38-47 pubmed publisher
    ..Three doses of a good whole-cell pertussis vaccine were 83...
  24. Rozenbaum M, De Cao E, Postma M. Cost-effectiveness of pertussis booster vaccination in the Netherlands. Vaccine. 2012;30:7327-31 pubmed publisher
    ..To conclude, we show that extended pertussis booster vaccination strategies are likely to be considered as cost-effective...
  25. Hawken S, Manuel D, Deeks S, Kwong J, Crowcroft N, Wilson K. Underestimating the safety benefits of a new vaccine: the impact of acellular pertussis vaccine versus whole-cell pertussis vaccine on health services utilization. Am J Epidemiol. 2012;176:1035-42 pubmed publisher
    The population-level safety benefits of the acellular pertussis vaccine may have been underestimated because only specific adverse events were considered, not overall impact on health services utilization...
  26. Lavine J, King A, Bjørnstad O. Natural immune boosting in pertussis dynamics and the potential for long-term vaccine failure. Proc Natl Acad Sci U S A. 2011;108:7259-64 pubmed publisher
  27. Skerry C, Mahon B. A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model. Clin Vaccine Immunol. 2011;18:187-93 pubmed publisher
    ..pertussis infection in antibody-deficient mice following passive transfer. This study suggests that BPZE1 is capable of conferring a high level of long-lived effective protection against virulent B. pertussis. ..
  28. Cheng P, Huang S, Shaw S, Kao C, Chueh H, Chang S, et al. Factors influencing women's decisions regarding pertussis vaccine: A decision-making study in the Postpartum Pertussis Immunization Program of a teaching hospital in Taiwan. Vaccine. 2010;28:5641-7 pubmed publisher
    ..Awareness about pertussis, its risk to infants, and prevention via vaccination need to be further increased among women of child-bearing age, particularly pregnant women. ..
  29. Zepp F, Heininger U, Mertsola J, Bernatowska E, Guiso N, Roord J, et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis. 2011;11:557-70 pubmed publisher
  30. Ross P, Sutton C, Higgins S, Allen A, Walsh K, Misiak A, et al. Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine. PLoS Pathog. 2013;9:e1003264 pubmed publisher
    ..Our findings demonstrate that alum promotes protective immunity through IL-1?-induced IL-17A production, but also reveal that optimum protection against B. pertussis requires induction of Th1, but not Th2 cells. ..
  31. Wiley K, Massey P, Cooper S, Wood N, Quinn H, Leask J. Pregnant women's intention to take up a post-partum pertussis vaccine, and their willingness to take up the vaccine while pregnant: a cross sectional survey. Vaccine. 2013;31:3972-8 pubmed publisher
    ..for post-partum pertussis vaccination among Australian pregnant women, and their willingness to accept pertussis vaccine during pregnancy, should it be recommended in Australia in the future...
  32. Hallander H, Advani A, Riffelmann M, von König C, Caro V, Guiso N, et al. Bordetella pertussis strains circulating in Europe in 1999 to 2004 as determined by pulsed-field gel electrophoresis. J Clin Microbiol. 2007;45:3257-62 pubmed
    ..It is therefore of major interest to continue with surveillance programs of B. pertussis isolates, as both waning vaccine-derived immunity and strain variation may play a role in the persistence of pertussis. ..
  33. Hallander H, Andersson M, Gustafsson L, Ljungman M, Netterlid E. Seroprevalence of pertussis antitoxin (anti-PT) in Sweden before and 10 years after the introduction of a universal childhood pertussis vaccination program. APMIS. 2009;117:912-22 pubmed publisher
  34. Bottero D, Gaillard M, Fingermann M, Weltman G, Fernández J, Sisti F, et al. Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains. Clin Vaccine Immunol. 2007;14:1490-8 pubmed
    ..Groups of mice were immunized either with diphtheria-tetanus-whole-cell pertussis vaccine (ptxS1B prn1) or a vaccine prepared by us containing B. pertussis 106...
  35. Berbers G, de Greeff S, Mooi F. Improving pertussis vaccination. Hum Vaccin. 2009;5:497-503 pubmed
  36. Xing D, Wirsing von Konig C, Newland P, Riffelmann M, Meade B, Corbel M, et al. Characterization of reference materials for human antiserum to pertussis antigens by an international collaborative study. Clin Vaccine Immunol. 2009;16:303-11 pubmed publisher
    ..In addition, the candidate material coded 06/142 has been proposed as a WHO working preparation for characterization of assay systems. ..
  37. Thalen M, van der Ark A, van den IJssel J, van Straaten I, Jansen D, Beuvery C, et al. Improving the cellular pertussis vaccine: increased potency and consistency. Vaccine. 2008;26:653-63 pubmed
    ..The stability of the NVP-THIJS product remained higher than the NVP-96 product over a period of 2 years, while the decline of the potency of both suspensions was comparable. ..
  38. Zorzeto T, Higashi H, da Silva M, Carniel E, Dias W, Ramalho V, et al. Immunogenicity of a whole-cell pertussis vaccine with low lipopolysaccharide content in infants. Clin Vaccine Immunol. 2009;16:544-50 pubmed publisher
    ..immune response and anti-pertussis toxin (anti-PT) immunoglobulin G (IgG) titers induced by a cellular pertussis vaccine with low lipopolysaccharide (LPS) content (wP(low) vaccine) with those induced by the conventional whole-..
  39. Grgic Vitek M, Klavs I, Kraigher A. Re-emergence of pertussis in Slovenia: time to change immunization policy. Vaccine. 2008;26:1874-8 pubmed publisher
    ..A booster dose at school entrance or latest at 8 years of age should be introduced to decrease the transmission of disease among school children and to further reduce the burden of disease among infants. ..
  40. Knuf M, Schmitt H, Wolter J, Schuerman L, Jacquet J, Kieninger D, et al. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. J Pediatr. 2008;152:655-60, 660.e1 pubmed publisher
    ..Birth dose of aP did not induce immunologic tolerance to pertussis antigens but appear to dampen responses to Hib and HBV vaccines. ..
  41. Locht C. A common vaccination strategy to solve unsolved problems of tuberculosis and pertussis?. Microbes Infect. 2008;10:1051-6 pubmed publisher
  42. Dirix V, Verscheure V, Goetghebuer T, Hainaut M, Debrie A, Locht C, et al. Cytokine and antibody profiles in 1-year-old children vaccinated with either acellular or whole-cell pertussis vaccine during infancy. Vaccine. 2009;27:6042-7 pubmed publisher
    ..In addition, the global Th2 bias observed in 6-month-old infants vaccinated with a Pa vaccine was normalized at 13 months. ..
  43. Gall S. Prevention of pertussis, tetanus, and diphtheria among pregnant, postpartum women, and infants. Clin Obstet Gynecol. 2012;55:498-509 pubmed publisher
    ..Tdap is highly immunogenetic in the pregnant women and has an excellent safety profile. Tdap given to the postpartum patient and her cocoon family is an alternative strategy...
  44. Zhang S, Xu Y, Zhou Z, Wang S, Yang R, Wang J, et al. Complete genome sequence of Bordetella pertussis CS, a Chinese pertussis vaccine strain. J Bacteriol. 2011;193:4017-8 pubmed publisher
    ..Here, we report the genome sequence of Bordetella pertussis strain CS, isolated from an infant patient in Beijing and widely used as a vaccine strain for production of an acellular pertussis vaccine in China.
  45. Lavine J, Bjørnstad O, De Blasio B, Storsaeter J. Short-lived immunity against pertussis, age-specific routes of transmission, and the utility of a teenage booster vaccine. Vaccine. 2012;30:544-51 pubmed publisher
    ..We aim to assess the duration of vaccine-induced immunity, and the possibility for a teenage-booster vaccine to protect infants in Norway...
  46. Kohberger R, Jemiolo D, Noriega F. Prediction of pertussis vaccine efficacy using a correlates of protection model. Vaccine. 2008;26:3516-21 pubmed publisher
    ..Follow-up of these subjects the model also predicted sustained and comparable efficacy for the combination and separate vaccines (75%) up to the pre-school booster age. ..
  47. Fedele G, Bianco M, Debrie A, Locht C, Ausiello C. Attenuated Bordetella pertussis vaccine candidate BPZE1 promotes human dendritic cell CCL21-induced migration and drives a Th1/Th17 response. J Immunol. 2011;186:5388-96 pubmed publisher
    ..A novel live attenuated Bordetella pertussis vaccine strain, BPZE1, has been developed by eliminating or detoxifying three important B...
  48. Cornford Nairns R, Daggard G, Mukkur T. Construction and preliminary immunobiological characterization of a novel, non-reverting, intranasal live attenuated whooping cough vaccine candidate. J Microbiol Biotechnol. 2012;22:856-65 pubmed
    ..b>pertussis vaccine candidate, which were substantially enhanced upon second exposure to virulent B. pertussis...
  49. Alexander F, Matheson M, Fry N, Labram B, Gorringe A. Antibody responses to individual Bordetella pertussis fimbrial antigen Fim2 or Fim3 following immunization with the five-component acellular pertussis vaccine or to pertussis disease. Clin Vaccine Immunol. 2012;19:1776-83 pubmed publisher
    ..distinct fimbriae (Fim2 and Fim3) which are included in the Sanofi Pasteur 5-component acellular pertussis vaccine, and antibody responses to these antigens have been shown to be associated with protection...
  50. Rozenbaum M, De Cao E, Westra T, Postma M. Dynamic models for health economic assessments of pertussis vaccines: what goes around comes around. Expert Rev Vaccines. 2012;11:1415-28 pubmed publisher
    ..In future, dynamic transmission models for pertussis should be used widely to further enhance understanding of pertussis epidemiology and of extended pertussis vaccination programs that are currently considered in various countries...
  51. Quinn H, McIntyre P. Pertussis epidemiology in Australia over the decade 1995-2005--trends by region and age group. Commun Dis Intell Q Rep. 2007;31:205-15 pubmed
    ..Immunisation Program for pertussis during the decade 1995-2005, including the introduction of acellular pertussis vaccine for all doses, removal from the schedule of the booster dose at 18 months, and the introduction of a booster ..
  52. Schnoeller C, Roux X, Sawant D, Raze D, Olszewska W, Locht C, et al. Attenuated Bordetella pertussis vaccine protects against respiratory syncytial virus disease via an IL-17-dependent mechanism. Am J Respir Crit Care Med. 2014;189:194-202 pubmed publisher
    ..Prevention of RSV infection by BPZE1 seems in part to be caused by induction of IL-17. Clinical trial registered with (NCT 01188512). ..
  53. Leuridan E, Hens N, Peeters N, de Witte L, Van Der Meeren O, Van Damme P. Effect of a prepregnancy pertussis booster dose on maternal antibody titers in young infants. Pediatr Infect Dis J. 2011;30:608-10 pubmed publisher
  54. Wood N, McIntyre P, Marshall H, Roberton D. Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age. Pediatr Infect Dis J. 2010;29:209-15 pubmed publisher
    ..responses to pertussis vaccines at birth but no previous study has evaluated 2 doses of monovalent acellular pertussis vaccine (aPV) before 2 months of age...
  55. Dalby T, Petersen J, Harboe Z, Krogfelt K. Antibody responses to pertussis toxin display different kinetics after clinical Bordetella pertussis infection than after vaccination with an acellular pertussis vaccine. J Med Microbiol. 2010;59:1029-36 pubmed publisher
    ..pertussis infection and for 20 Danish adults booster-vaccinated with an acellular pertussis vaccine. For both groups, biphasic decay was seen, but the individual antibody responses varied greatly...
  56. Mooi F. Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen. Infect Genet Evol. 2010;10:36-49 pubmed publisher
    ..pertussis populations has not only increased our understanding of pathogen evolution, but also suggests way to improve pertussis vaccines, underlining the public health significance of population-based studies of pathogens. ..
  57. Zhang X, Rodriguez M, Harvill E. O antigen allows B. parapertussis to evade B. pertussis vaccine-induced immunity by blocking binding and functions of cross-reactive antibodies. PLoS ONE. 2009;4:e6989 pubmed publisher
    ..parapertussis prevalence varies substantially between populations with different vaccination strategies...
  58. Hendrikx L, Berbers G, Veenhoven R, Sanders E, Buisman A. IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content. Vaccine. 2009;27:6530-6 pubmed publisher
    ..The aim of this study is to investigate IgG responses in whole cell (wP) and acellular (aP) pertussis vaccine primed children following revaccination with different pertussis booster vaccines at 4 years of age...
  59. Lavine J, Broutin H, Harvill E, Bjørnstad O. Imperfect vaccine-induced immunity and whooping cough transmission to infants. Vaccine. 2010;29:11-6 pubmed publisher
    ..In addition, the data indicate that the B. pertussis vaccine is not protective against disease induced by B. parapertussis.
  60. Zhu Y, Cai C, Zhang W, Guo H, Zhang J, Ji Y, et al. Immunoproteomic analysis of human serological antibody responses to vaccination with whole-cell pertussis vaccine (WCV). PLoS ONE. 2010;5:e13915 pubmed publisher
    ..2-DE), immunoblotting, and mass spectrometry to reveal the entire antigenic proteome of whole-cell pertussis vaccine (WCV) targeted by the human immune system as a first step toward evaluating the repertoire of human humoral ..
  61. Witt M, Katz P, Witt D. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin Infect Dis. 2012;54:1730-5 pubmed publisher
    ..It has been suggested that acellular vaccine may be less effective than previously believed. During a large outbreak, we examined the incidence of pertussis and effectiveness of vaccination in a well-vaccinated, well-defined community...
  62. Bouchez V, Brun D, Cantinelli T, Dore G, Njamkepo E, Guiso N. First report and detailed characterization of B. pertussis isolates not expressing Pertussis Toxin or Pertactin. Vaccine. 2009;27:6034-41 pubmed publisher
    ..All isolates were found less pathogen in animal or cellular models; their circulation raises the problem of clinical and biological diagnoses...
  63. Rohani P, Zhong X, King A. Contact network structure explains the changing epidemiology of pertussis. Science. 2010;330:982-5 pubmed publisher
    ..The practical implications of our results are notable: Ignoring age-structured contacts is likely to result in misinterpretation of epidemiological data and potentially costly policy missteps. ..
  64. Wearing H, Rohani P. Estimating the duration of pertussis immunity using epidemiological signatures. PLoS Pathog. 2009;5:e1000647 pubmed publisher
    ..Our results support a period of natural immunity that is, on average, long-lasting (at least 30 years) but inherently variable...
  65. Fabricius G, Bergero P, Ormazabal M, Maltz A, Hozbor D. Modelling pertussis transmission to evaluate the effectiveness of an adolescent booster in Argentina. Epidemiol Infect. 2013;141:718-34 pubmed publisher
    ..An effort to improve the coverage of the first dose would have a much greater impact on infants. These results hold in the 18 scenarios considered, which demonstrates the robustness of these conclusions...
  66. Garlapati S, Eng N, Kiros T, Kindrachuk J, Mutwiri G, Hancock R, et al. Immunization with PCEP microparticles containing pertussis toxoid, CpG ODN and a synthetic innate defense regulator peptide induces protective immunity against pertussis. Vaccine. 2011;29:6540-8 pubmed publisher
  67. Feunou P, Bertout J, Locht C. T- and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis. PLoS ONE. 2010;5:e10178 pubmed publisher
    ..parapertussis and did not protect SCID mice against B. parapertussis infection. The novel live attenuated pertussis vaccine BPZE1 protects in a pre-clinical mouse model against B...
  68. Dalby T, Seier Petersen M, Kristiansen M, Harboe Z, Krogfelt K. Problem solved: a modified enzyme-linked immunosorbent assay for detection of human antibodies to pertussis toxin eliminates false-positive results occurring at analysis of heat-treated sera. Diagn Microbiol Infect Dis. 2009;63:354-60 pubmed publisher
    ..This ELISA modification is straightforward and cheap, and it should be recommended at all analyses incorporating sera with unknown history of heat exposure. ..
  69. Fry N, Litt D, Duncan J, Vaghji L, Warrener L, Samuel D, et al. Modelling anti-pertussis toxin IgG antibody decay following primary and preschool vaccination with an acellular pertussis vaccine in UK subjects using a modified oral fluid assay. J Med Microbiol. 2013;62:1281-9 pubmed publisher
    Recent vaccination with pertussis vaccine can confound serological and oral fluid (OF) assays targeting anti-pertussis toxin (anti-PT) IgG antibodies as a marker of recent infection...
  70. Vermeulen F, Verscheure V, Damis E, Vermeylen D, Leloux G, Dirix V, et al. Cellular immune responses of preterm infants after vaccination with whole-cell or acellular pertussis vaccines. Clin Vaccine Immunol. 2010;17:258-62 pubmed publisher
    ..We conclude that like full-term infants, most preterm infants are able to mount a specific cellular immune response to the administration of the first doses of an acellular or a whole-cell pertussis vaccine.
  71. Rendi Wagner P, Tobias J, Moerman L, Goren S, Bassal R, Green M, et al. The seroepidemiology of Bordetella pertussis in Israel--Estimate of incidence of infection. Vaccine. 2010;28:3285-90 pubmed publisher
    ..pertussis, particularly in adolescents and elderly. Population-based serosurveillance for pertussis offers the potential to assist interpretation of trends independent of notification and diagnostic bias. ..